Doença papuloescamosa crônica rara, de etiologia desconhecida, caracterizada por pequenas pápulas foliculares, manchas vermelho-alaranjadas escamosas e hiperqueratose palmoplantar, que pode progredir para placas ou eritrodermia. Embora a maioria dos casos seja esporádica e adquirida, existe uma forma familiar da doença.
Introdução
O que você precisa saber de cara
Doença papuloescamosa crônica rara, de etiologia desconhecida, caracterizada por pequenas pápulas foliculares, manchas vermelho-alaranjadas escamosas e hiperqueratose palmoplantar, que pode progredir para placas ou eritrodermia. Embora a maioria dos casos seja esporádica e adquirida, existe uma forma familiar da doença.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 22 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant, Not applicable.
Acts as a scaffolding protein that can activate the inflammatory transcription factor NF-kappa-B and p38/JNK MAP kinase signaling pathways. Forms a signaling complex with BCL10 and MALT1, and activates MALT1 proteolytic activity and inflammatory gene expression. MALT1 is indispensable for CARD14-induced activation of NF-kappa-B and p38/JNK MAP kinases (PubMed:11278692, PubMed:21302310, PubMed:27071417, PubMed:27113748). May play a role in signaling mediated by TRAF2, TRAF3 and TRAF6 and protects
Cytoplasm
Psoriasis 2
A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.
Medicamentos aprovados (FDA)
1 medicamento encontrado nos registros da FDA americana.
Variantes genéticas (ClinVar)
82 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 1,236 variantes classificadas pelo ClinVar.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Pytiriasis rubra pilosa
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
6 ensaios clínicos encontrados, 2 ativos.
Publicações mais relevantes
Successful Treatment of Pityriasis Rubra Pilaris With Deucravacitinib.
This case report describes a woman in her 60s who presented with a 2-month history of rapidly progressive erythematous skin lesions that began on the upper extremities and gradually spread to the buttocks and lower limbs and was diagnosed with pityriasis rubra pilaris.
CARD14-Associated Papulosquamous Eruption (CAPE): An Updated Review of Pathogenesis and Treatment.
CARD14-associated papulosquamous eruption (CAPE) is a rare genetically mediated inflammatory skin disorder caused by gain-of-function variants in the CARD14 gene. It typically presents in infancy or early childhood with clinical features resembling both psoriasis and pityriasis rubra pilaris, and often exhibits a poor response to conventional therapies. An increasing number of studies support favorable outcomes with biologic medications, particularly interleukin (IL)-12/23 and IL-17 inhibitors, for the treatment of CAPE. This literature review summarizes the etiology and pathophysiology of CAPE, with a focus on clinical features, genetic findings, and developments in treatment strategies.
Case Report: Successful treatment of pityriasis rubra pilaris with deucravacitinib.
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease characterized by hyperkeratotic follicular papules, palmoplantar hyperkeratosis, and associated normal "islands of unaffected skin". Its pathogenesis has not been fully elucidated, and treatment poses significant challenges. Conventional therapies include oral retinoids and topical emollients. In recent years, although biological agents have been used in treatment, they are associated with side effects such as an increased risk of infection, and some patients show no response to treatment, thus necessitating the exploration of new therapeutic approaches.This case represents the first reported use of a TYK2 inhibitor (deucravacitinib) for the treatment of PRP. The patient was a 39-year-old male who developed extensive erythema in December 2024. The erythema gradually increased and progressed to red punctate eruptions accompanied by mild desquamation, slight pruritus with a stinging sensation, and "islands of unaffected skin". Initial treatment with topical dinoprostone and mometasone furoate cream was ineffective. In March 2025, the patient received deucravacitinib (6 mg daily) in combination with topical halometasone cream. At the 1-month follow-up, significant improvements were observed in erythema, desquamation, and pruritus. At the final 6-month follow-up, the skin lesions almost resolved, leaving only mild erythema and a small amount of desquamation. Both the disease severity and the patient's quality of life were significantly improved. This case suggests that deucravacitinib exhibits favorable efficacy and safety in the treatment of PRP. However, due to the low incidence of PRP, which makes large-scale controlled trials difficult, and the lack of recognized treatment guidelines, more clinical studies are needed in the future to further verify the potential of deucravacitinib in the treatment of PRP.
Vitamins and the skin: Vitamin A and retinoids in dermatology.
Vitamin A and analogs are widely used in dermatology, with retinoids being natural and synthetic vitamin A derivatives. Topical retinoids (especially tretinoin and tretinoin precursors) can diminish photoaging and contribute to the thickening and restoration of skin collagen. Retinoids used as therapeutic agents include oral retinoids (eg, isotretinoin, acitretin, alitretinoin, and bexarotene) and topical retinoids (eg, isotretinoin, tretinoin, adapalene, tazarotene, and trifarotene). Although retinoids have traditionally been used for skin disorders of keratinization, such as psoriasis, pityriasis rubra pilaris, Darier disease, and ichthyoses, there is a variety of indications of retinoids for the treatment of skin diseases, including diseases of the pilosebaceous unit such as acne vulgaris, pigmentary disorders such as melasma, or cutaneous malignancies such as cutaneous T-cell lymphoma. Other retinoids with distinct routes of administration (oral or topical) and distinct dosing or safety profiles are recommended for different skin disorders. We discuss the mode of action and indications of retinoids used as pharmacologic agents in dermatology and provide an update on their use, effectiveness, and tolerability.
Pityriasis rubra pilaris triggered by vaccination.
Pityriasis rubra pilaris (PRP) is a rare inflammatory papulo-squamous skin disease. To date, the exact etiopathogenesis of PRP is unknown; although the most accepted triggers are viral or bacterial infections, few cases after vaccination have been reported as well. Our aim is to conduct a systematic review of cases of PRP triggered by vaccination. The PubMed and Scopus databases were searched for articles concerning PRP post-vaccination, published between January 2000 and June 2024. We also added a previously unpublished case that came to our attention. Twenty-three articles were included, and 30 cases have been identified. The majority of patients were male (20/30, 66.6%). The median age of onset was 55 years (min 17 months-max 85 years). Most patients (27/30, 90%) were adults vaccinated against SARS-CoV-2, of whom 14/27 (51.9%) received mRNA-based vaccines (9 Comirnaty/Pfizer and 5 Spikevax/Moderna). The three pediatric cases had been vaccinated against Measles-Mumps-Rubella (2 cases) and intramuscular diphtheria-tetanus-pertussis vaccine plus oral poliovirus. The temporal relationship between vaccination and PRP onset varied (median 10 days post-vaccination; min 2-max 30). PRP occurred both after the first dose (14/30, 46.6%) and at subsequent doses of the vaccine. The majority of patients re-exposed to new doses (6/9, 66%) experienced clinical exacerbation. Post-vaccination PRP responds well to both traditional and biologic treatments, with only 4/30 (13.3%) showing no resolution. In conclusion, PRP post-vaccination is rare and likely underdiagnosed, but recognizing the association is important to evaluate any new exposures to the trigger. A thorough patient history, including recent vaccinations, is crucial.
Publicações recentes
The use of upadacitinib for refractory pityriasis rubra pilaris: A case report.
Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP-GPP Overlap.
Comparing Clinical vs Histopathological Features in Diagnosing Erythemato-Squamous Diseases.
Successful Treatment of Pityriasis Rubra Pilaris with Upadacitinib: Report of Two Cases.
CARD14-Associated Papulosquamous Eruption (CAPE): An Updated Review of Pathogenesis and Treatment.
📚 EuropePMC800 artigos no totalmostrando 195
CARD14-Associated Papulosquamous Eruption (CAPE): An Updated Review of Pathogenesis and Treatment.
International journal of dermatologyTyrosine Kinase 2 Inhibition for Refractory Pityriasis Rubra Pilaris in Two Cases.
International journal of dermatologyFamilial CARD14-associated papulosquamous eruption with a novel mutation successfully treated with secukinumab.
JAAD case reportsVaccination-Induced Pityriasis Rubra Pilaris: A Systematic Review.
Journal of cutaneous medicine and surgeryCase Report: Successful treatment of pityriasis rubra pilaris with deucravacitinib.
Frontiers in immunologyVitamins and the skin: Vitamin A and retinoids in dermatology.
Clinics in dermatologySuccessful Treatment of Pityriasis Rubra Pilaris With Deucravacitinib.
JAMA dermatologyType IV pityriasis rubra pilaris treated with ixekizumab.
Anais brasileiros de dermatologiaNavigating the Misdiagnosis of Pityriasis Rubra Pilaris and Successful Treatment With Guselkumab: A Case Report of Dual Biologic Therapy.
CureusStriking linear presentation of type I pityriasis rubra pilaris in a young man.
Clinical and experimental dermatologyPityriasis rubra pilaris triggered by vaccination.
Italian journal of dermatology and venereologyPityriasis Rubra Pilaris With Hypereosinophilia: Answer.
The American Journal of dermatopathologyCytokine-associated pathogenic profile as a guide for targeted therapy in pityriasis rubra pilaris.
Journal of the European Academy of Dermatology and Venereology : JEADVPsoriasis in the Context of Dermatologic Disorders: A Comprehensive Overview.
Diseases (Basel, Switzerland)Paraneoplastic pityriasis rubra pilaris: a systematic review.
Clinical and experimental dermatologyHIV-Associated Pityriasis Rubra Pilaris Type 6: First Case Report from Türkiye.
Infectious diseases & clinical microbiologyTofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris-A Case Report.
Clinical case reportsRegressed anterior mediastinal nodule secondary to removal of dental crowns.
Journal of surgical case reportsDiagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting.
The Journal of rheumatologyPediatric Pityriasis Rubra Pilaris Treated With Secukinumab: A Case Report.
The Journal of dermatologyRefractory pityriasis rubra pilaris treated with abrocitinib.
Dermatology reportsPsoriasis and Papulosquamous Disorders.
Primary careArtificial intelligence for the diagnosis of erythematous-squamous dermatological diseases: technological contributions to primary care.
Anais brasileiros de dermatologiaAre Blue Straggler Stars a Hidden Clue? Intriguing Discovery in Pityriasis Rubra Pilaris Under UV-Induced Fluorescence Dermoscopy.
Dermatology practical & conceptualEfficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights.
Dermatology practical & conceptualPrecision, Research, Progress: Updates in the Management of Pityriasis Rubra Pilaris.
Journal of drugs in dermatology : JDDCase Report: Successful treatment of a novel variant of CARD14-mutated juvenile Pityriasis rubra pilaris with ixekizumab.
Frontiers in medicineSorafenib-Induced Pityriasis Rubra Pilaris-like Eruption: A Case Report.
Indian dermatology online journalQuality of Life Assessment Among Patients with Papulosquamous Disorders in Southern Nigeria.
West African journal of medicineTreatment of refractory pityriasis rubra pilaris with biologic therapy: a case series.
Clinical and experimental dermatologyPityriasis rubra pilaris with symmetric polyarthritis and lymphadenopathy.
BMJ case reportsSymmetrical intertriginous drug-related flexural exanthema-like presentation in paediatric patients following bone marrow transplant: think graft-versus-host disease.
Clinical and experimental dermatologyComplete Resolution of Pityriasis Rubra Pilaris With Targeted Treatment: A Case Report.
CureusClinicopathological and management outcome in 70 patients with pityriasis rubra pilaris: A retrospective analysis.
Indian journal of dermatology, venereology and leprologyIL-17C and Pityriasis Rubra Pilaris: Successful Treatment of Erythroderma With Brodalumab.
International journal of dermatologyPityriasis rubra pilaris following Shingrix vaccine: a report of two cases.
Clinical and experimental dermatologyClassical Juvenile Pityriasis Rubra Pilaris Treated With Secukinumab: Case Report and a Review of Biological Treatments in the Pediatric Population.
Pediatric dermatologyCase Report of Dermatomyositis With Features of the Wong Variant Developing Post-Trastuzumab Therapy for Breast Cancer.
The Australasian journal of dermatology[Translated article] Facial Discoid Dermatosis. A 13-Case Series.
Actas dermo-sifiliograficasEfficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris-A systematic review.
Frontiers in medicineSimilar Molecular Features in Two Cases of CARD14-Associated Papulosquamous Eruption.
The Australasian journal of dermatology[Nail changes in inflammatory dermatoses: recognition and treatment].
Dermatologie (Heidelberg, Germany)Pityriasis Rubra Pilaris Following COVID-19 Infection: A Case of Successful Treatment With Ixekizumab.
CureusKLK11-Related Disorder of Cornification Presenting as Inflammatory Skin Disease: A Familial Case Report and Literature Review.
American journal of medical genetics. Part ATreatment of pityriasis rubra pilaris with systemic and biological agents: A single-center retrospective cohort of 76 patients.
Journal of the American Academy of DermatologyTargeted dual biologic therapy for erythroderma of unknown etiology guided by high-parameter peripheral blood immunophenotyping.
Scientific reportsA case of pityriasis rubra pilaris secondary to ponatinib.
SAGE open medical case reportsCytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status.
Journal of cutaneous pathologyOff-label dermatologic uses of IL-23 inhibitors.
The Journal of dermatological treatmentAtypical adult type pityriasis rubra pilaris.
Indian journal of dermatology, venereology and leprologyGrover's disease-like patterns in early pityriasis rubra pilaris.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGUncommon Presentation of Pityriasis Rubra Pilaris of the Scalp: Clinical, Trichoscopic, and Histopathologic Features and Review of the Literature.
Medicina (Kaunas, Lithuania)Erythroderma in the elderly.
The Journal of dermatologyPityriasis rubra pilaris.
Journal of the American Academy of DermatologyIatrogenic Hypertriglyceridemia when Treating Pityriasis Rubra Pilaris: An algorithm for Monitoring and Treatment during Retinoid Therapy.
SkinmedLong-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient.
Clinical, cosmetic and investigational dermatologyA young female with rapid progression of erythroderma and palmoplantar keratoderma.
International journal of rheumatic diseasesRevisiting risankizumab: a newer biologic drug in dermatology.
Italian journal of dermatology and venereologyErythroderma Following Pfizer-BioNTech COVID-19 Vaccination in a Patient With Atopic Dermatitis: A Case Report.
CureusPityriasis rubra pilaris and underlying malignancy.
QJM : monthly journal of the Association of PhysiciansPityriasis rubra pilaris with eosinophilia in a young patient: a case report.
Annals of medicine and surgery (2012)Wong-Type Dermatomyositis: Literature Review of a Rare Variant.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesOff-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis.
Life (Basel, Switzerland)Clinical Characteristics and Treatment Patterns of Pityriasis Rubra Pilaris: A Canadian Retrospective Study.
Journal of cutaneous medicine and surgerySuccessful Treatment of Refractory Extensive Pityriasis Rubra Pilaris With Risankizumab and Acitretin.
CutisPityriasis Rubra Pilaris in an Atopic Dermatitis Patient: A Case Report.
CureusTofacitinib for Pityriasis Rubra Pilaris: A Case Report.
Clinical, cosmetic and investigational dermatologyEmerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris.
Life (Basel, Switzerland)Hyperactivation of the IL-17 Axis and IL-36 Signaling in Card14-Mutant Pityriasis Rubra Pilaris Mouse Model.
The Journal of investigative dermatologyGuselkumab - In Psoriasis and Beyond.
Dermatology practical & conceptualSevere atypical juvenile pityriasis rubra pilaris diagnosed in adulthood with a dramatic improvement with ustekinumab.
Skin health and diseaseA case report of refractory advanced-stage mycosis fungoides: successful treatment and improved patient quality of life with mogamulizumab.
Therapeutic advances in hematologySuccessful Treatment of Generalized Pustular Psoriasis Coexisting with Pityriasis Rubra Pilaris with Upadacitinib.
Indian journal of pediatricsLoss-of-function mutations in Keratin 32 gene disrupt skin immune homeostasis in pityriasis rubra pilaris.
Nature communicationsJAAD Game Changers: CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris.
Journal of the American Academy of DermatologyRapid clearance of extensive juvenile pityriasis rubra pilaris with ixekizumab.
Pediatric dermatologySevere pityriasis rubra pilaris complicated with Kaposi's varicelliform eruption and cutaneous MRSA infection case report.
HeliyonPityriasis Rubra Pilaris - a difficult path to optimal treatment. Case report.
Polski merkuriusz lekarski : organ Polskiego Towarzystwa LekarskiegoTargeting IL-1 controls refractory pityriasis rubra pilaris.
Science advancesPost-infectious pityriasis rubra pilaris in pediatric patients.
Archivos argentinos de pediatriaRole of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris.
Archives of dermatological researchSurgical Management of Severe Cicatricial Ectropion Secondary to Pityriasis Rubra Pilaris.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]Erythrodermic Pityriasis Rubra Pilaris Following COVID-19 Vaccination.
CutisTildrakizumab use for recalcitrant pityriasis rubra pilaris.
The Australasian journal of dermatologyRisankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma.
JAAD case reportsOphthalmic complication of pityriasis rubra pilaris.
BMJ case reportsSuccessful treatment of pityriasis rubra pilaris with brodalumab after nonresponse to IL-17A inhibition: A role for the innate cytokine IL-17C.
JAAD case reportsEarly Gestational Diabetes Mellitus: An Update.
The Journal of the Association of Physicians of IndiaInappropriate Use of Steroids in Superficial Dermatophytosis: An Uncommon Case of Erythroderma.
The Journal of the Association of Physicians of IndiaRapid improvement of severe pityriasis rubra pilaris upon treatment with bimekizumab.
International journal of dermatologyPityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab.
Anais brasileiros de dermatologiaTwo Incidental Sibling Diagnoses of Netherton Syndrome in Separate Visits: A Case Report.
CureusPityriasis following COVID-19 vaccinations: a systematic review.
Dermatology reportsGuselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial.
JAMA dermatologyEfficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris.
Journal of the European Academy of Dermatology and Venereology : JEADVBiologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review.
Journal of cutaneous medicine and surgeryDiseases categorized as autoinflammatory keratinization diseases (AiKDs), and their pathologies and treatments.
Nagoya journal of medical sciencePityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients.
Actas dermo-sifiliograficasCase report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel CARD14 mutation.
Frontiers in medicineAn Institution Based Cross-Sectional Observational Aetiological Study Correlating the Clinico-Pathological Findings in Patients Presenting with Acquired Palmoplantar Keratoderma.
Indian journal of dermatologySezary syndrome initially presenting as pityriasis rubra pilaris: Clinicopathologic study of 3 cases.
JAAD case reportsDelayed Presentation of Pityriasis Rubra Pilaris in a Patient on Treatment With Ponatinib.
CureusResolution of Pityriasis rubra pilaris induced ectropion with oral dexamethasone. A case report.
Orbit (Amsterdam, Netherlands)Key Factors in the Complex and Coordinated Network of Skin Keratinization: Their Significance and Involvement in Common Skin Conditions.
International journal of molecular sciencesUpdates on Pityriasis Rubra Pilaris: A Scoping Review.
Journal of cutaneous medicine and surgeryPityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options.
American journal of clinical dermatologyHIV: Inflammatory dermatoses.
Clinics in dermatologyBiologics for inherited disorders of keratinisation: A systematic review.
The Australasian journal of dermatologyAutoinflammatory Keratinization Diseases-The Concept, Pathophysiology, and Clinical Implications.
Clinical reviews in allergy & immunologySuccessful treatment of erythrodermic pityriasis rubra pilaris with upadacitinib.
Journal of the European Academy of Dermatology and Venereology : JEADVPonatinib Induced Pityriasis Rubra Pilaris: Case Report and Review of Literature.
Indian dermatology online journalUtility of Dermoscopy in the Diagnosis of Erythroderma: A Cross-Sectional Study.
Indian dermatology online journalCase report: Area of focus of management of severe pityriasis rubra pilaris by dose optimization of adalimumab biosimilar in combination with acitretin and montelukast.
Frontiers in medicineSuccessful treatment of CARD14-negative juvenile Pityriasis rubra pilaris with Ustekinumab.
Journal of the European Academy of Dermatology and Venereology : JEADVBimekizumab in refractory pityriasis rubra pilaris.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGMethotrexate and acitretin in pityriasis rubra pilaris: A retrospective cohort study.
Journal of the American Academy of DermatologyErythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab.
JAAD case reportsEosinophils in Traditionally Noneosinophil-Rich Dermatoses.
The American Journal of dermatopathologyRapid response of erythrodermic pityriasis rubra pilaris to tildrakizumab.
Clinical and experimental dermatologyWong-type dermatomyositis with interstitial lung disease and anti-SRP and -PM/Scl antibodies treated with intravenous immunoglobulin.
JAAD case reportsCorrigendum to "Successful treatment of a child's pityriasis rubra pilaris (PRP)with ustekinumab and acitretin"1.
Pediatric dermatologyAcute Exfoliative Dermatitis/Erythroderma Secondary to Gliclazide.
CureusPatients with keratinization disorders due to ABCA12 variants showing pityriasis rubra pilaris phenotypes.
The Journal of dermatologyPatient-reported cutaneous signs and symptoms of adult pityriasis rubra pilaris and correlation with quality of life and clinician-reported severity: A cross-sectional study.
Journal of the American Academy of DermatologyA Rare Post-infectious Rash: Pityriasis Rubra Pilaris After COVID-19 Infection.
CureusSuccessful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children.
Dermatology and therapyNail Whispers Revealing Dermatological and Systemic Secrets: An Analysis of Nail Disorders Associated With Diverse Dermatological and Systemic Conditions.
CureusA case of paraneoplastic pityriasis rubra pilaris.
JAAD case reportsBiologic treatment options for pityriasis rubra pilaris: An evidence-based systematic review.
Journal of the American Academy of DermatologyThe individual Pityriasis Rubra Pilaris area and severity index (iPRPASI): validity, reliability, and responsiveness of a novel patient-reported severity tool.
Archives of dermatological researchThe Effectiveness of Anti-Interleukin-17A Treatment for Pityriasis Rubra Pilaris: A Systematic Review.
CureusPityriasis rubra pilaris with simultaneous emergence of human herpesvirus-6 reactivation in a patient with drug-induced hypersensitivity syndrome.
The Journal of dermatologyPityriasis rubra pilaris induced by topical use of imiquimod 5.
Anais brasileiros de dermatologiaKaposi's Varicelliform Eruption After Treatment With Ixekizumab in a Patient With Pityriasis Rubra Pilaris.
CureusA child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab.
Pediatric dermatologyA case of follicular psoriasis mimicking pityriasis rubra pilaris: a diagnostic dilemma.
International journal of dermatologyA case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab.
The Australasian journal of dermatologyJuvenile Pityriasis Rubra Pilaris.
Dermatology practical & conceptualMisdiagnosed Pityriasis Rubra Pilaris Successfully Managed With Isotretinoin: A Case Series.
CureusRefractory pityriasis rubra pilaris treated with upadacitinib.
JAAD case reportsPityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab.
JAAD case reportsPityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report.
SAGE open medical case reportsClinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination.
Journal of the European Academy of Dermatology and Venereology : JEADVPityriasis Rubra Pilaris Significantly Improved after Treatment for Chronic Focal Infection.
Indian journal of dermatologyJuvenile Pityriasis Rubra Pilaris in a 4-year-old Child Treated Successfully with Secukinumab.
Indian journal of dermatologyA novel mutation in a CARD14-associated papulosquamous eruption.
Pediatric dermatologyPityriasis rubra pilaris type IV-associated arthritis treated with adalimumab.
International journal of rheumatic diseasesRethinking pityriasis rubra pilaris as a paraneoplastic syndrome: Two cases of pityriasis rubra pilaris with concomitant underlying malignancy.
JAAD case reportsA case of bullous pemphigoid developing after ixekizumab therapy for pityriasis rubra pilaris.
The Journal of dermatologyPityriasis Rubra Pilaris After Moderna COVID-19 Vaccination: A Case Report and Literature Review.
The American Journal of dermatopathologyCutaneous and Developmental Effects of CARD14 Overexpression in Zebrafish.
BiomedicinesTreatment Options for Juvenile Pityriasis Rubra Pilaris.
Paediatric drugsPityriasis rubra pilaris following inactivated SARS-CoV-2 vaccine (CoronaVac).
Journal of the European Academy of Dermatology and Venereology : JEADVPonatinib-Associated Cutaneous Eruptions-A Case Series and Review of Clinicopathologic Findings.
The American Journal of dermatopathologyPhysiotherapy Management of an Adolescent With Pityriasis Rubra Pilaris Along With Rickets.
CureusPityriasis rubra pilaris with rickets: a rare clinical image.
The Pan African medical journalAtypical Juvenile Pityriasis Rubra Pilaris: A Case Report of Early Onset With Late Diagnosis.
CureusPityriasis rubra pilaris heralding diagnosis of urothelial carcinoma: a case report.
Dermatology online journalSuccessful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris.
Clinical case reportsSuccessful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child.
Dermatologic therapyOff-label uses of ustekinumab.
Dermatologic therapyPityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: Successful treatment with ustekinumab and acitretin.
Dermatologic therapyPityriasis Rubra Pilaris Transcriptomics Implicate T Helper 17 Signaling and Correlate with Response to Ixekizumab, with Distinct Gene Expression Profiles in Nonresponders.
The Journal of investigative dermatologyA Case of Ichthyosis Vulgaris and the Use of 70% Glycolic Acid Chemical Peels for Management.
CureusEfficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: A case series.
The Australasian journal of dermatologyPityriasis rubra pilaris rapidly cleared with ixekizumab in an HIV-positive patient.
JAAD case reportsPityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine.
Dermatologic therapyAnti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave.
The British journal of dermatologyCOVID-19 induced pityriasis rubra pilaris: A superantigenic disease?
Journal of the European Academy of Dermatology and Venereology : JEADVEarly Presentation of Pityriasis Rubra Pilaris Mimicking Tinea Corporis: Diagnostic Challenges of a Rare Skin Condition.
The American journal of case reportsPityriasis rubra pilaris with erythema gyratum repens-like eruption and resolution with ustekinumab.
Clinical and experimental dermatologySuccessful treatment of pityriasis rubra pilaris with risankizumab, a IL-23/p19 antagonist.
Journal of the European Academy of Dermatology and Venereology : JEADVIxekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination.
Skin health and diseaseClinical course, diagnostic patterns, and treatment outcomes in patients with pityriasis rubra pilaris.
Journal of the American Academy of DermatologySuccessful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy.
Clinical and experimental dermatologyPatient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.
The British journal of dermatologyUstekinumab-Induced Fatal Acute Heart Failure in a Young Female: A Case Report.
Methodist DeBakey cardiovascular journalSuccessful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin.
Pediatric dermatologyParaneoplastic Pityriasis Rubra Pilaris Preceding Leukemia.
Advances in skin & wound careSecukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
The British journal of dermatologyBeyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes.
Current opinion in rheumatologyCutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor.
Skin health and diseaseDelayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review.
JAAD case reportsErythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection.
Journal of the European Academy of Dermatology and Venereology : JEADVA case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine.
JAAD case reportsPityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine.
JAAD case reportsA case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report.
SAGE open medical case reportsAcute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: Decoding a possible trigger!!
Journal of cosmetic dermatologyEine neue Form der juvenilen Pityriasis rubra pilaris mit möglicher Beteiligung bakterieller Superantigene.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGPityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac).
Dermatologic therapy[Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?].
Dermatologie (Heidelberg, Germany)Pityriasis rubra pilaris (type I) following ChAdOx1 COVID-19 vaccine: A report of two cases with successful treatment with oral isotretinoin.
Journal of the European Academy of Dermatology and Venereology : JEADVDermoscopy of Gottron's papules and other inflammatory dermatoses involving the dorsa of the hands.
Journal of the European Academy of Dermatology and Venereology : JEADVClinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.
The British journal of dermatologyKeratosis pilaris rubra successfully treated with topical sirolimus: Report of a case and review of the literature.
Pediatric dermatologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Pytiriasis rubra pilosa.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Pytiriasis rubra pilosa
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Successful Treatment of Pityriasis Rubra Pilaris With Deucravacitinib.
- CARD14-Associated Papulosquamous Eruption (CAPE): An Updated Review of Pathogenesis and Treatment.
- Case Report: Successful treatment of pityriasis rubra pilaris with deucravacitinib.
- Vitamins and the skin: Vitamin A and retinoids in dermatology.
- Pityriasis rubra pilaris triggered by vaccination.
- The use of upadacitinib for refractory pityriasis rubra pilaris: A case report.
- Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP-GPP Overlap.
- Comparing Clinical vs Histopathological Features in Diagnosing Erythemato-Squamous Diseases.
- Successful Treatment of Pityriasis Rubra Pilaris with Upadacitinib: Report of Two Cases.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:2897(Orphanet)
- OMIM OMIM:173200(OMIM)
- MONDO:0008251(MONDO)
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
- Q766856(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
